Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6010 + SG001 in 1L Advanced/Metastatic ESCC
NCT07251062Phase 3Not yet recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Dec 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 3, randomised, open-label trial of CPO301 in Esophageal Squamous Cell Carcinoma (ESCC) (7 arms), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd. Primary endpoints: Dose-limiting toxicity at 28 days, Adverse Events and 5 more. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
CPO301
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07251062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07251062.